OCE 2.0? US FDA Leadership Change May Present Opportunity To Grant Full Review Authority
With a new commissioner expected next year, a restructuring may allow the Oncology Center of Excellence to assume sign-off authority for biologics and devices along with drugs.
You may also be interested in...
Cures 2.0 Would Mandate More FDA Centers of Excellence But Oncology-Style Funding Gaps Could Doom Plan
The two new intercenter institutes, one to focus on a common group of diseases and the other on rare diseases, appear to be unfunded mandates, which could hinder the agency’s ability to get them up and running.
President Biden’s pick for FDA commissioner should remember many of the hot-button issues that he would face upon confirmation, such as drug pricing and approval standards.
Creation of agency's new Oncology Center of Excellence means the Office of Hematology and Oncology Products, often seen as FDA's model product review shop, needs new leadership – at least temporarily.